Research Paper Volume 11, Issue 15 pp 5463—5482
Large-scale analysis reveals the specific clinical and immune features of CD155 in glioma
Figure 6. Association between CD155 and immune checkpoint markers in glioma. Correlation between CD155 and immune checkpoint markers (PD-L1, PD-L2, NR2F6, and B7-H2) in gliomas (A) and GBM (B) in Rembrandt dataset were subjected to the analysis. Correlation between CD155 and immune checkpoint markers (PD-L1, PD-L2, NR2F6, and B7-H2) in gliomas (C) and GBM (D) in TCGA were also included.